---
title: 848
description: 
published: true
date: 2026-01-24T20:03:00.920Z
tags: editor: FreeODwikiæ˜¯ä¸€ä¸ªä»¥å¼€æºå…±äº«ä¸ºå®—æ—¨ï¼Œæä¾›æœ‰å…³ODã€Overdoseã€è¯ç‰©æ»¥ç”¨ã€è¯ç‰©è¿‡é‡ã€å¸æ¯’ã€æ¯’å“ã€ç¦æ¯’ç­‰è¯é¢˜çš„é¡¹ç›®ã€‚
dateCreated: 2026-01-24T20:02:58.130Z
---
ğŸ¦ æ™®ç‘å·´æ—/DXMæˆ’æ–­æœŸçš„è”åˆç”¨è¯ç­–ç•¥
===================================================

æ‰˜å¡é…¯ä¹‹æ‰€ä»¥è¢«é€‰ä¸­ç”¨äºè¿™ä¸¤ç±»ç‰©è´¨çš„æˆç˜¾æ²»ç–—ï¼Œæ˜¯å› ä¸ºå…¶è¯ç†æœºåˆ¶æ°å¥½è¦†ç›–äº†DXMå’ŒPGBçš„ç—…ç†ç”Ÿç†é¶ç‚¹ã€‚

å®ƒæ—¢èƒ½å¢å¼ºGABAä»‹å¯¼çš„æŠ‘åˆ¶æ€§ä¼ å¯¼ï¼Œåˆèƒ½æ‹®æŠ—AMPA/Kainateå‹è°·æ°¨é…¸å—ä½“ï¼ŒåŒæ—¶è°ƒèŠ‚ç”µå‹é—¨æ§é’ é€šé“å’Œé’™é€šé“ ã€‚è¿™ç§â€œå¤šé¶ç‚¹â€ç‰¹æ€§ä½¿å…¶èƒ½å¤Ÿåœ¨åˆ†å­æ°´å¹³ä¸Šçº æ­£ç”±æˆç˜¾ç‰©è´¨å¼•èµ·çš„ç¥ç»é€’è´¨å¤±è¡¡ï¼Œå°¤å…¶æ˜¯åœ¨æŠ‘åˆ¶è°·æ°¨é…¸èƒ½è¿‡åº¦å…´å¥‹æ–¹é¢å…·æœ‰ç‹¬ç‰¹ä¼˜åŠ¿ã€‚

æ‰˜å¡é…¯çš„åŒ–å­¦ç»“æ„ä¸ºç£ºèƒºå–ä»£çš„å•ç³–ï¼Œè¿™ç§ç‹¬ç‰¹çš„ç»“æ„èµ‹äºˆäº†å®ƒä¸å…¶ä»–æŠ—ç™«ç—«è¯ç‰©æˆªç„¶ä¸åŒçš„è¯  
ç†ç‰¹æ€§ã€‚ç†è§£è¿™äº›æœºåˆ¶æ˜¯åˆ¶å®šä¸´åºŠæ–¹æ¡ˆçš„åŸºç¡€ã€‚

è°·æ°¨é…¸èƒ½ç³»ç»Ÿçš„è°ƒèŠ‚ï¼šAMPAä¸Kainateå—ä½“æ‹®æŠ—
--------------------------------------------------------

è°·æ°¨é…¸æ˜¯ä¸­æ¢ç¥ç»ç³»ç»Ÿä¸»è¦çš„å…´å¥‹æ€§é€’è´¨ï¼Œåœ¨æˆç˜¾è®°å¿†çš„å½¢æˆã€æ¸´æ±‚çš„äº§ç”Ÿä»¥åŠæˆ’æ–­æœŸçš„å…´å¥‹æ€§  
æ¯’æ€§ä¸­æ‰®æ¼”æ ¸å¿ƒè§’è‰²ã€‚

â— Kainateå—ä½“ï¼ˆGluK1/GluR5ï¼‰çš„é€‰æ‹©æ€§æŠ‘åˆ¶ï¼š ç ”ç©¶è¡¨æ˜ï¼Œæ‰˜å¡é…¯åœ¨æä»æ ¸åŸºåº•å¤–ä¾§æ ¸ï¼ˆBasolateral Amygdala, BLAï¼‰èƒ½å¤Ÿé€‰æ‹©æ€§åœ°æŠ‘åˆ¶å«æœ‰GluR5äºšåŸºçš„Kainateå—ä½“ ã€‚

æä»æ ¸æ˜¯å¤„ç†æƒ…ç»ªè®°å¿†å’Œææƒ§ååº”çš„å…³é”®è„‘åŒºï¼Œä¹Ÿæ˜¯æˆç˜¾å¾ªç¯ä¸­â€œè´Ÿæ€§å¼ºåŒ–â€å’Œâ€œæ¸´æ±‚â€çš„ç¥ç»è§£å‰–å­¦åŸºç¡€ã€‚é€šè¿‡é˜»æ–­è¿™ä¸€é€šè·¯ï¼Œæ‰˜å¡é…¯èƒ½å¤Ÿç›´æ¥å‰Šå¼±ç”±è¯ç‰©çº¿ç´¢ï¼ˆCuesï¼‰è¯±å‘çš„æ¡ä»¶æ€§æ¸´æ±‚ååº”ã€‚

è¿™ä¸€ç‚¹åœ¨é…’ç²¾ä¾èµ–çš„ç ”ç©¶ä¸­å·²å¾—åˆ°è¯å®ï¼Œä¸”å¯¹äºDXMè¿™ç§æœ¬èº«å¹²æ‰°è°·æ°¨é…¸ç³»ç»Ÿçš„è¯ç‰©æˆç˜¾å°¤ä¸ºé‡è¦ ã€‚

â— AMPAå—ä½“çš„æ‹®æŠ—ï¼š æ‰˜å¡é…¯åŒæ—¶ä¹Ÿæ‹®æŠ—AMPAå—ä½“ã€‚AMPAå—ä½“ä»‹å¯¼äº†ç»å¤§å¤šæ•°å¿«é€Ÿå…´å¥‹æ€§  
çªè§¦ä¼ é€’ã€‚åœ¨æˆ’æ–­çŠ¶æ€ä¸‹ï¼Œçªè§¦åè†œAMPAå—ä½“çš„ä»£å¿æ€§ä¸Šè°ƒæ˜¯å¯¼è‡´ç¥ç»å…ƒè¿‡åº¦å…´å¥‹çš„ä¸»  
è¦åŸå› ã€‚æ‰˜å¡é…¯çš„é˜»æ–­ä½œç”¨æœ‰åŠ©äºå¹³æŠ‘è¿™ç§ç—…ç†æ€§çš„å…´å¥‹æµªæ½®ï¼Œä»è€Œç¼“è§£æˆ’æ–­ç—‡çŠ¶ ã€‚

GABAèƒ½ç³»ç»Ÿçš„å¢å¼ºï¼šéè‹¯äºŒæ°®å“ç±»æœºåˆ¶
-------------------------------------------------

GABAæ˜¯ä¸»è¦çš„æŠ‘åˆ¶æ€§é€’è´¨ã€‚æ‰˜å¡é…¯é€šè¿‡ä¸€ç§ç‹¬ç‰¹çš„å˜æ„è°ƒèŠ‚æœºåˆ¶å¢å¼ºGABA\_Aå—ä½“çš„æ´»æ€§ ã€‚

â— ç‹¬ç‰¹ç»“åˆä½ç‚¹ï¼š ä¸è‹¯äºŒæ°®å“ç±»è¯ç‰©ç»“åˆäºGABAå—ä½“çš„ç‰¹å®šä½ç‚¹ä¸åŒï¼Œæ‰˜å¡é…¯çš„ä½œç”¨ä½ç‚¹å°šæœªå®Œå…¨æ˜ç¡®ï¼Œä½†å·²çŸ¥å…¶å¹¶ä¸ç«äº‰è‹¯äºŒæ°®å“æˆ–å·´æ¯”å¦¥ç±»ä½ç‚¹ã€‚è¿™ä¸ä»…æ„å‘³ç€æ‰˜å¡é…¯æœ¬èº«ç¼ºä¹æ»¥ç”¨æ½œåŠ›ï¼Œè¿˜æ„å‘³ç€å®ƒåœ¨è‹¯äºŒæ°®å“è€å—çš„æ‚£è€…ä¸­ä¾ç„¶æœ‰æ•ˆ ã€‚

â— æ°¯ç¦»å­æµå¢åŠ ï¼š æ‰˜å¡é…¯å¢åŠ GABAæ¿€æ´»çš„æ°¯ç¦»å­å†…æµé¢‘ç‡ï¼Œå¯¼è‡´ç¥ç»å…ƒè¶…æåŒ–ã€‚

è¿™ç§æ•ˆåº”ä¸ºæˆ’æ–­æœŸç„¦è™‘å’Œæ¿€è¶Šæä¾›äº†ç”Ÿç†å­¦ä¸Šçš„â€œåˆ¹è½¦â€æœºåˆ¶ï¼Œå¯¹äºæ™®ç‘å·´æ—æˆ’æ–­å¼•èµ·çš„ä¸¥é‡ç„¦è™‘å°¤ä¸ºå…³é”® ã€‚

ç¦»å­é€šé“çš„è°ƒèŠ‚ï¼šç”µå‹é—¨æ§é’ é€šé“ä¸é’™é€šé“
---------------------------------------------------------

ç”µå‹é—¨æ§é’ é€šé“ï¼ˆVGSCsï¼‰ï¼š æ‰˜å¡é…¯ä»¥çŠ¶æ€ä¾èµ–æ€§ï¼ˆState\-dependentï¼‰çš„æ–¹å¼é˜»æ–­é’ é€šé“ï¼Œå³ä¼˜å…ˆæŠ‘åˆ¶é‚£äº›å¤„äºå¿«é€Ÿã€é‡å¤æ”¾ç”µçŠ¶æ€çš„ç¥ç»å…ƒï¼Œè€Œå¯¹æ­£å¸¸æ”¾ç”µçš„ç¥ç»å…ƒå½±å“è¾ƒå°ã€‚è¿™ä½¿å¾—å®ƒèƒ½åœ¨ä¸ä¸¥é‡æŠ‘åˆ¶æ­£å¸¸è„‘åŠŸèƒ½çš„å‰æä¸‹ï¼Œç‰¹å¼‚æ€§åœ°æ§åˆ¶æˆ’æ–­æœŸçš„ç¥ç»å…ƒè¿‡åº¦å…´å¥‹ ã€‚

â— é«˜ç”µå‹æ¿€æ´»é’™é€šé“ï¼ˆL\-type Calcium Channelsï¼‰ï¼š æ‰˜å¡é…¯å¯¹Lå‹é’™é€šé“å…·æœ‰è´Ÿå‘è°ƒèŠ‚ä½œç”¨ã€‚é’™ç¦»å­å†…æµæ˜¯ç¥ç»é€’è´¨é‡Šæ”¾çš„è§¦å‘æ‰³æœºã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œæ‰˜å¡é…¯å¯¹Lå‹é’™ç”µæµçš„æŠ‘åˆ¶å‘ˆç°å‡ºéçº¿æ€§çš„åŒç›¸æ•ˆåº”ï¼ˆBiphasic concentration\-responseï¼‰ï¼Œè¿™æ„å‘³ç€å…¶è°ƒèŠ‚ä½œç”¨æ˜¯ç²¾ç»†ä¸”å¤æ‚çš„ ã€‚

é‰´äºæ™®ç‘å·´æ—ä¸»è¦ä½œç”¨äºé’™é€šé“çš„Î±2Î´äºšåŸºï¼Œæ‰˜å¡é…¯å¯¹é’™é€šé“çš„è°ƒèŠ‚ä½œç”¨æä¾›äº†ä¸€ç§æœºåˆ¶ä¸Šçš„äº’è¡¥æˆ–æ›¿ä»£ï¼Œæœ‰åŠ©äºåœ¨æ™®ç‘å·´æ—æ’¤é™¤åç»´æŒé’™ç¨³æ€ ã€‚

ç¢³é…¸é…é…¶æŠ‘åˆ¶ä¸ç»†èƒå†…ä¿¡å·è½¬å¯¼
------------------------------------------

æ‰˜å¡é…¯æ˜¯ç¢³é…¸é…é…¶ï¼ˆç‰¹åˆ«æ˜¯CA\-IIå’ŒCA\-IVåŒå·¥é…¶ï¼‰çš„å¼±æŠ‘åˆ¶å‰‚ã€‚è™½ç„¶è¿™ä¸€ä½œç”¨å¹¶éå…¶æŠ—ç™«ç—«æˆ–æŠ—æˆç˜¾çš„ä¸»è¦æœºåˆ¶ï¼Œä½†å®ƒç›´æ¥å¯¼è‡´äº†ä¸´åºŠä¸Šå¸¸è§çš„å‰¯ä½œç”¨ï¼Œå¦‚ä»£è°¢æ€§é…¸ä¸­æ¯’ã€æ„Ÿè§‰å¼‚å¸¸ï¼ˆParesthesiaï¼‰å’Œè‚¾ç»“çŸ³é£é™© ã€‚åœ¨ç»†èƒå†…å±‚é¢ï¼Œæ‰˜å¡é…¯è¿˜å½±å“è†œè›‹ç™½çš„ç£·é…¸åŒ–çŠ¶æ€ï¼ˆå¦‚PKCé€šè·¯ï¼‰ï¼Œè¿™å¯èƒ½æ¶‰åŠé•¿æœŸçš„ç¥ç»å¯å¡‘æ€§è°ƒèŠ‚ï¼Œæœ‰åŠ©äºä¿®å¤æˆç˜¾å¤§è„‘çš„çªè§¦ç»“æ„å¼‚å¸¸ ã€‚

å³ç¾æ²™èŠ¬çš„ç¥ç»æ¯’æ€§ä¸æˆç˜¾å¾ªç¯
------------------------------------------

å³ç¾æ²™èŠ¬ï¼ˆDXMï¼‰ï¼š ä½œä¸ºå—å•¡å–ƒçš„å³æ—‹å¼‚æ„ä½“ï¼ŒDXMåœ¨è¯ç†ä¸Šä¸é˜¿ç‰‡å—ä½“æ— äº²å’ŒåŠ›ï¼Œå´è¡¨ç°å‡ºå¤æ‚çš„ç¥ç»æ´»æ€§ã€‚å…¶æ ¸å¿ƒæˆç˜¾æœºåˆ¶åœ¨äºå¯¹N\-ç”²åŸº\-D\-å¤©å†¬æ°¨é…¸ï¼ˆNMDAï¼‰å—ä½“çš„éç«äº‰æ€§æ‹®æŠ—ä½œç”¨ï¼Œä»¥åŠå¯¹Sigma\-1å—ä½“çš„æ¿€åŠ¨ä½œç”¨ ã€‚

è¿™ç§æœºåˆ¶ä¸æ°¯èƒºé…®é«˜åº¦ç›¸ä¼¼ï¼Œèƒ½å¤Ÿè¯±å¯¼ä¸€ç§è¢«ç§°ä¸ºâ€œåˆ†ç¦»æ€§éº»é†‰â€çš„çŠ¶æ€ï¼Œä½¿ç”¨è€…åœ¨æ»¥ç”¨å‰‚é‡ä¸‹ä¼šä½“éªŒåˆ°ç°å®æ„Ÿä¸§å¤±ã€è§†å¹»è§‰åŠè®¤çŸ¥æ‰­æ›²ã€‚

å¯¹äºå…±ç—…æŠ‘éƒæˆ–åŒç›¸éšœç¢çš„æ‚£è€…ï¼Œè¿™ç§è§£ç¦»çŠ¶æ€å¸¸è¢«ç”¨ä½œé€ƒé¿ç—›è‹¦æƒ…ç»ªçš„åº”å¯¹æœºåˆ¶

å³ç¾æ²™èŠ¬çš„æ»¥ç”¨ä¸ä»…ä»…æ˜¯è¿½æ±‚â€œå¿«æ„Ÿâ€ï¼Œæ›´æ˜¯ä¸€ç§é€šè¿‡åŒ–å­¦æ‰‹æ®µè¯±å¯¼çš„è§£ç¦»ä½“éªŒã€‚å…¶ä½œä¸ºéç«äº‰æ€§NMDAæ‹®æŠ—å‰‚ï¼Œé˜»æ–­äº†è°·æ°¨é…¸ä¸NMDAå—ä½“çš„ç»“åˆï¼Œå¯¼è‡´çš®å±‚\-ä¸˜è„‘é€šè·¯çš„ä¿¡å·æ•´åˆä¸­æ–­ã€‚é•¿æœŸå¤„äºè¿™ç§è°·æ°¨é…¸é˜»æ–­çŠ¶æ€ï¼Œå¤§è„‘ä¼šäº§ç”Ÿé€‚åº”æ€§æ”¹å˜ï¼šçªè§¦åè†œNMDAå—ä½“å’ŒAMPAå—ä½“å¯†åº¦ä»£å¿æ€§ä¸Šè°ƒ

å½“æ»¥ç”¨è€…çªç„¶åœæ­¢æ‘„å…¥DXMæ—¶ï¼Œå¤–æºæ€§çš„é˜»æ–­è§£é™¤ï¼Œå†…æºæ€§è°·æ°¨é…¸ä½œç”¨äºè¿™äº›æ•°é‡å€å¢çš„å—ä½“ï¼Œå¯¼è‡´çŒ›çƒˆçš„è°·æ°¨é…¸åå¼¹ã€‚è¿™ç§â€œè°·æ°¨é…¸é£æš´â€ä¸ä»…å¼•èµ·ä¸¥é‡çš„ç”Ÿç†æˆ’æ–­ç—‡çŠ¶ï¼Œè¿˜ä¼šå¯¼è‡´å…´å¥‹æ€§ç¥ç»æ¯’æ€§ï¼Œè¡¨ç°ä¸ºè®¤çŸ¥åŠŸèƒ½ä¸‹é™å’Œæƒ…ç»ªå¤±æ§

æ‰˜å¡é…¯æ²»ç–—DXMæˆç˜¾çš„ç†è®ºä¾æ®ä¸å®è¯
------------------------------------------------

é’ˆå¯¹DXMæˆç˜¾çš„ç—…ç†æœºåˆ¶ï¼Œæ‰˜å¡é…¯æä¾›äº†ä¸€ç§â€œåå‘è§£æ¯’â€ç­–ç•¥ï¼š

ç›´æ¥å¯¹æŠ—å—ä½“ä¸Šè°ƒï¼š æ‰˜å¡é…¯æ‹®æŠ—AMPA/Kainateå—ä½“ï¼Œç›´æ¥å‰Šå¼±äº†æˆ’æ–­æœŸè°·æ°¨é…¸åå¼¹çš„å†²å‡»åŠ›ï¼Œä¿æŠ¤ç¥ç»å…ƒå…å—å…´å¥‹æ€§æ¯’æ€§æŸä¼¤ï¼Œå¹¶å‡è½»æˆ’æ–­ç—‡çŠ¶ã€‚

æ›¿ä»£è§£ç¦»éœ€æ±‚ï¼š è™½ç„¶æ‰˜å¡é…¯æœ¬èº«ä¸äº§ç”Ÿè§£ç¦»å¿«æ„Ÿï¼Œä½†å…¶é€šè¿‡æŠ‘åˆ¶è°·æ°¨é…¸å’Œå¢å¼ºGABAäº§ç”Ÿçš„é•‡é™å’ŒæŠ—ç„¦è™‘ä½œç”¨ï¼Œå¯ä»¥ç¼“è§£å¯¼è‡´æ‚£è€…å¯»æ±‚è§£ç¦»çš„å†…åœ¨ç—›è‹¦

RamaswamyæŠ¥å‘Šä¸GRIK1åŸºå› å¤šæ€æ€§
--------------------------------------

Sriram Ramaswamyç­‰äººå‘è¡¨çš„ç—…ä¾‹æŠ¥å‘Šä¸ºæ‰˜å¡é…¯æ²»ç–—DXMæˆç˜¾æä¾›äº†ç›´æ¥çš„ä¸´åºŠè¯æ® ã€‚

æ¡ˆä¾‹æ¦‚å†µï¼š è¯¥æŠ¥å‘Šæè¿°äº†ä¸€åæ‚£æœ‰ä¸¥é‡å³ç¾æ²™èŠ¬ä¾èµ–çš„æ‚£è€…ï¼Œè¯¥æ‚£è€…å¯èƒ½åˆå¹¶æœ‰æƒ…ç»ªéšœç¢ã€‚å¸¸è§„  
æ²»ç–—æœªèƒ½æ§åˆ¶å…¶å¯¹DXMçš„å¼ºçƒˆæ¸´æ±‚ã€‚

æ²»ç–—å¹²é¢„ï¼š åŒ»ç–—å›¢é˜Ÿç»éªŒæ€§åœ°ä½¿ç”¨äº†æ‰˜å¡é…¯è¿›è¡Œæ²»ç–—ã€‚ç»“æœæ˜¾ç¤ºï¼Œæ‚£è€…çš„æ¸´æ±‚æ˜¾è‘—é™ä½ï¼ŒæˆåŠŸå®  
ç°äº†åœè¯ã€‚

é—ä¼ å­¦æœºåˆ¶ï¼š è¯¥æ¡ˆä¾‹æœ€å¼•äººæ³¨ç›®çš„å‘ç°æ˜¯æ‚£è€…çš„åŸºå› å‹ã€‚åŸºå› æ£€æµ‹æ˜¾ç¤ºï¼Œè¯¥æ‚£è€…æ˜¯GRIK1  
rs2832407 (C:C) ç­‰ä½åŸºå› çš„æºå¸¦è€…ã€‚GRIK1åŸºå› ç¼–ç Kainateå—ä½“çš„GluR5äºšåŸºã€‚å…ˆå‰çš„é…’ç²¾ä¾  
èµ–ç ”ç©¶å·²ç»è¯å®ï¼Œæºå¸¦C:CåŸºå› å‹çš„ä¸ªä½“å¯¹æ‰˜å¡é…¯çš„æ²»ç–—ååº”æ˜¾è‘—ä¼˜äºå…¶ä»–åŸºå› å‹ ã€‚

â— æœºåˆ¶è§£é‡Šï¼š C:CåŸºå› å‹å¯èƒ½å¯¼è‡´GluR5å—ä½“çš„åŠŸèƒ½æˆ–è¡¨è¾¾å‘ç”Ÿç‰¹å®šæ”¹å˜ï¼Œä½¿å¾—è¯¥äºšç¾¤å—ä½“å¯¹æ‰˜å¡é…¯çš„æŠ‘åˆ¶ä½œç”¨æ›´ä¸ºæ•æ„Ÿã€‚ç”±äºDXMæˆç˜¾æ¶‰åŠè°·æ°¨é…¸ç³»ç»Ÿçš„ä»£å¿æ€§æ”¹å˜ï¼Œè¿™ç§é—ä¼ èƒŒæ™¯ä½¿å¾—æ‰˜å¡é…¯èƒ½å¤Ÿæ›´ç²¾å‡†åœ°é€šè¿‡GluR5é€šè·¯é˜»æ–­æ¸´æ±‚ã€‚

è¿™ä¸€å‘ç°å¼ºè°ƒäº†åœ¨éš¾æ²»æ€§DXMæˆç˜¾æ²»ç–—ä¸­å¼•å…¥**è¯ç‰©åŸºå› ç»„å­¦ï¼ˆPharmacogenomicsï¼‰**ç­›æŸ¥çš„é‡  
è¦æ€§ã€‚å¯¹äºæºå¸¦GRIK1 C:CåŸºå› å‹çš„æ‚£è€…ï¼Œæ‰˜å¡é…¯åº”è¢«è§†ä¸ºä¸€çº¿æ²»ç–—é€‰æ‹©ã€‚

æ™®ç‘å·´æ—ä¾èµ–çš„ç—…ç†ç”Ÿç†ä¸æ‰˜å¡é…¯å¹²é¢„
---------------------------------------------------

å°½ç®¡æ™®ç‘å·´æ—è¢«è®¾è®¡ä¸ºä¸€ç§ä½æˆç˜¾æ€§çš„è¯ç‰©ï¼Œä½†ä¸´åºŠç°å®è¡¨æ˜ï¼Œå…¶åœ¨å¤§å‰‚é‡ä¸‹å…·æœ‰æ˜¾è‘—çš„æ»¥ç”¨æ½œ  
åŠ›ã€‚å…¶æœºåˆ¶æ¶‰åŠè°ƒèŠ‚è„‘å†…å¥–èµç³»ç»Ÿçš„é’™ä¾èµ–æ€§ç¥ç»é€’è´¨é‡Šæ”¾ã€‚é•¿æœŸæš´éœ²äºæ™®ç‘å·´æ—ä¼šå¯¼è‡´Î±2Î´\-1äºš  
åŸºå¯†åº¦çš„ä¸‹è°ƒæˆ–å…¶ä»–é€‚åº”æ€§æ”¹å˜ ã€‚

æ™®ç‘å·´æ—è™½ç„¶æ˜¯GABAçš„ç»“æ„ç±»ä¼¼ç‰©ï¼Œä½†å¹¶ä¸ç›´æ¥ç»“åˆGABAå—ä½“ï¼Œè€Œæ˜¯é«˜äº²å’ŒåŠ›åœ°ç»“åˆäºç”µå‹é—¨æ§é’™é€šé“ï¼ˆVGCCï¼‰çš„Î±2Î´\-1è¾…åŠ©äºšåŸº ã€‚é€šè¿‡æŠ‘åˆ¶è¿‡åº¦å…´å¥‹ç¥ç»å…ƒçš„é’™ç¦»å­å†…æµï¼Œå®ƒå‡å°‘äº†è°·æ°¨é…¸ã€å»ç”²è‚¾ä¸Šè…ºç´ å’ŒPç‰©è´¨çš„çªè§¦å‰é‡Šæ”¾ã€‚

ç„¶è€Œï¼Œé•¿æœŸå¤§å‰‚é‡ä½¿ç”¨å¯¼è‡´ç¥ç»ç³»ç»Ÿäº§ç”Ÿé€‚åº”æ€§æ”¹å˜ï¼Œéª¤åœæ—¶ä¼šå‡ºç°ä¸¥é‡çš„å…´å¥‹æ€§åè·³ï¼Œè¡¨ç°ä¸ºæåº¦ç„¦è™‘ã€å¤±çœ ã€ç”šè‡³ç™«ç—«å‘ä½œï¼Œè¿™ç§å¼ºçƒˆçš„ç”Ÿç†æˆ’æ–­ååº”æ˜¯ç»´æŒæˆç˜¾è¡Œä¸ºçš„å…³é”®é©±åŠ¨åŠ› ã€‚

æ™®ç‘å·´æ—æˆ’æ–­ç»¼åˆå¾ï¼š å½“è¯ç‰©éª¤åœæ—¶ï¼Œé’™é€šé“åŠŸèƒ½çš„å»æŠ‘åˆ¶å¯¼è‡´å…´å¥‹æ€§é€’è´¨ï¼ˆç‰¹åˆ«æ˜¯å»ç”²è‚¾ä¸Šè…ºç´ å’Œè°·æ°¨é…¸ï¼‰çš„è¿‡åº¦é‡Šæ”¾ã€‚ä¸´åºŠè¡¨ç°æå…·ç ´åæ€§ï¼ŒåŒ…æ‹¬ï¼š

â— ä¸¥é‡ç„¦è™‘ä¸æ¿€è¶Šï¼š å¾€å¾€æ¯”åŸå‘æ€§ç„¦è™‘éšœç¢æ›´ä¸ºå‰§çƒˆã€‚

â— å¤±çœ ï¼š æåº¦éš¾ä»¥å…¥ç¡ï¼Œä¼´æœ‰å¤šæ¢¦ã€‚

â— èº¯ä½“ç—‡çŠ¶ï¼š æ¶å¿ƒã€å¤šæ±—ã€è…¹æ³»ã€å¿ƒæ‚¸ã€å¤´ç—›ã€‚

â— ç¥ç»ç³»ç»Ÿç—‡çŠ¶ï¼š éœ‡é¢¤ã€å…±æµå¤±è°ƒï¼Œç”šè‡³ç™«ç—«å‘ä½œ ã€‚

æ‰˜å¡é…¯åœ¨æ™®ç‘å·´æ—æˆ’æ–­ç®¡ç†ä¸­çš„è§’è‰²
------------------------------------------------

ç›®å‰ï¼Œå…³äºæ‰˜å¡é…¯æ²»ç–—æ™®ç‘å·´æ—ä¾èµ–çš„ç›´æ¥åŒç›²å¯¹ç…§è¯•éªŒï¼ˆRCTï¼‰è¾ƒå°‘ï¼Œè¯æ®ä¸»è¦æ¥è‡ªäº¤å‰è¯ç†å­¦  
æ¨æ–­ã€åŠ¨ç‰©æ¨¡å‹åŠä¸´åºŠç»éªŒ ã€‚

æœºåˆ¶é‡å ä¸æ›¿ä»£æ•ˆåº”ï¼š è™½ç„¶æ‰˜å¡é…¯ï¼ˆä½œç”¨äºLå‹é’™é€šé“ï¼‰ä¸æ™®ç‘å·´æ—ï¼ˆä½œç”¨äºN/P/Qå‹é’™é€šé“çš„Î±2Î´  
äºšåŸºï¼‰çš„åˆ†å­é¶ç‚¹ä¸å®Œå…¨ç›¸åŒï¼Œä½†å®ƒä»¬åœ¨åŠŸèƒ½ä¸Šå…·æœ‰é«˜åº¦çš„äº’è¡¥æ€§ã€‚

é’™æµæ§åˆ¶çš„æ¥åŠ›ï¼š åœ¨æ™®ç‘å·´æ—å‡é‡è¿‡ç¨‹ä¸­ï¼Œç¥ç»å…ƒé’™å†…æµå€¾å‘äºå¢åŠ ã€‚æ‰˜å¡é…¯é€šè¿‡æŠ‘åˆ¶Lå‹é’™é€šé“ï¼Œå¯ä»¥éƒ¨åˆ†ä»£å¿è¿™ç§é’™æµå¤±æ§ï¼Œç»´æŒç¥ç»å…ƒçš„ç¨³å®šæ€§ã€‚

æŠ‘åˆ¶è°·æ°¨é…¸é£æš´ï¼š æ™®ç‘å·´æ—æˆ’æ–­å¯¼è‡´è°·æ°¨é…¸é‡Šæ”¾å¢åŠ ã€‚æ‰˜å¡é…¯ä½œä¸ºAMPA/Kainateæ‹®æŠ—å‰‚ï¼Œåœ¨çªè§¦åæ°´å¹³é˜»æ–­äº†è¿™äº›è¿‡é‡è°·æ°¨é…¸çš„æ•ˆåº”ï¼Œä»è€Œå‡è½»äº†ç„¦è™‘å’Œæ¿€è¶Š ã€‚

éæˆç˜¾æ€§é•‡é™ï¼š ä¸è‹¯äºŒæ°®å“ç±»è¯ç‰©ç›¸æ¯”ï¼Œæ‰˜å¡é…¯æ²¡æœ‰æˆç˜¾æ€§ï¼Œè¿™ä½¿å…¶æˆä¸ºé•¿æœŸç»´æŒæ²»ç–—ã€é¢„é˜²å¤å‘çš„ç†æƒ³é€‰æ‹©ï¼Œé¿å…äº†â€œç”¨ä¸€ç§æˆç˜¾è¯æ›¿ä»£å¦ä¸€ç§â€çš„é£é™© ã€‚

åŠ¨ç‰©ç ”ç©¶è¯æ®ï¼š åœ¨å¤§é¼ çš„å¤§éº»ç´ æˆ’æ–­æ¨¡å‹ä¸­ï¼ˆè¯¥æ¨¡å‹ä¸æ™®ç‘å·´æ—æˆ’æ–­å…±äº«éƒ¨åˆ†åº”æ¿€é€šè·¯ï¼‰ï¼Œç ”ç©¶å‘ç°æ‰˜å¡é…¯å’Œæ™®ç‘å·´æ—å‡èƒ½é˜»æ–­è„‘å†…é…ªæ°¨é…¸ç¾ŸåŒ–é…¶çš„ä¸‹è°ƒå’ŒCB1å—ä½“çš„ä¸Šè°ƒï¼Œæœ‰æ•ˆç¼“è§£æˆ’æ–­ç›¸å…³çš„ç„¦è™‘æ ·è¡Œä¸º ã€‚è¿™è¡¨æ˜ä¸¤è€…åœ¨è°ƒèŠ‚æˆ’æ–­åº”æ¿€ååº”ä¸Šå…·æœ‰å…±åŒçš„ä¸‹æ¸¸æ•ˆåº”ã€‚

å‰‚é‡æ»´å®šä¸ç»™è¯æ–¹æ¡ˆ
---------------------------

ç”±äºæ‰˜å¡é…¯çš„è®¤çŸ¥å‰¯ä½œç”¨ï¼ˆå¦‚æ‰¾è¯å›°éš¾ã€ååº”è¿Ÿé’ï¼‰å’Œè‡´æŠ‘éƒé£é™©ä¸å‰‚é‡å¢åŠ é€Ÿåº¦æ­£ç›¸å…³ï¼Œ**æ  
å…¶ç¼“æ…¢çš„æ»´å®š**æ˜¯æˆåŠŸçš„å…³é”®ã€‚  
æ¨èæ»´å®šæ—¶é—´è¡¨ï¼š ï¼ˆåŸºäºç™«ç—«å’Œé…’ç²¾ä¾èµ–çš„æ²»ç–—ç»éªŒåŠä¸­çš„æ•°æ®ï¼‰

| å‘¨æ•° | æ™¨é—´å‰‚é‡ (mg) | æ™šé—´å‰‚é‡ (mg | æ¯æ—¥æ€»å‰‚é‡ (mg) | ä¸´åºŠè¯´æ˜ |
| --- | --- | --- | --- | --- |
| ç¬¬1å‘¨ | 0 | 25 | 25 | æ™šé—´æœç”¨ä»¥å‡å°‘æ—¥é—´é•‡é™ |
| ç¬¬2å‘¨ | 25 | 25 | 50 | è§‚å¯Ÿæ˜¯å¦æœ‰çš®ç–¹æˆ–æ€¥æ€§æƒ…ç»ªå˜åŒ– |
| ç¬¬3å‘¨ | 25 | 50 | 75 | å¼€å§‹ç›‘æµ‹è®¤çŸ¥åŠŸèƒ½ |
| ç¬¬4å‘¨ | 50 | 50 | 100 | è®¸å¤šåŒç›¸æ‚£è€…çš„è€å—ä¸Šé™ |
| ç¬¬5\-6å‘¨ | 75 | 75 | 150 | è¯„ä¼°æ¸´æ±‚æ”¹å–„æƒ…å†µ |
| ç¬¬7\-8å‘¨ | 100 | 100 | 200 | æˆç˜¾æ²»ç–—çš„ç›®æ ‡å‰‚é‡é€šå¸¸ä¸º200\-300mg |


å…³é”®æ³¨æ„äº‹é¡¹ï¼š

ç›®æ ‡å‰‚é‡ï¼š é’ˆå¯¹æˆç˜¾æ§åˆ¶ï¼Œé€šå¸¸éœ€è¦è¾¾åˆ° **200\-300 mg**/å¤© ã€‚ä½†å¯¹äºåŒç›¸å…±ç—…æ‚£è€…ï¼Œè‹¥å‡ºç°æƒ…  
ç»ªä¸ç¨³ï¼Œåº”ç»´æŒåœ¨è¾ƒä½çš„æœ‰æ•ˆå‰‚é‡ï¼ˆå¦‚100\-150 mgï¼‰ã€‚

â— åœè¯åŸåˆ™ï¼š ä¸¥ç¦éª¤åœã€‚å¿…é¡»è¿›è¡Œç¼“æ…¢å‡é‡ï¼ˆTaperingï¼‰ï¼Œå»ºè®®æ¯3\-7å¤©å‡å°‘25\-50 mgï¼Œä»¥é˜²æ­¢ç™«  
ç—«å‘ä½œåå¼¹æˆ–æˆ’æ–­ç—‡çŠ¶æ¶åŒ– ã€‚

ç¬¬ä¸€é˜¶æ®µï¼šæ€¥æ€§æ’æ¯’æœŸï¼ˆç¬¬1\-7å¤©ï¼‰
----------------------------------------------

â— æ™®ç‘å·´æ—/åŠ å·´å–·ä¸çš„é€æ­¥å‡é‡ï¼š å»ºè®®æ™®ç‘å·´æ—æ¯å‘¨å‡å°‘50\-100 mgï¼Œæˆ–åŠ å·´å–·ä¸æ¯4å¤©å‡å°‘  
300 mg ã€‚

â— è‹¯äºŒæ°®å“ç±»è¯ç‰©ï¼š çŸ­æœŸä½¿ç”¨ï¼ˆå¦‚åœ°è¥¿æ³®ã€åŠ³æ‹‰è¥¿æ³®ï¼‰æ˜¯æ§åˆ¶æ€¥æ€§ä¸¥é‡ç„¦è™‘ã€éœ‡é¢¤å’Œé¢„é˜²ç™«ç—«å‘ä½œçš„æ ‡å‡† ã€‚

â— è¾…åŠ©è¯ç‰©ï¼š å¯ä¹å®š0\.1\-0\.3 mg/å¤©ï¼Œç”¨äºæ§åˆ¶è‡ªä¸»ç¥ç»äº¢è¿›ç—‡çŠ¶ï¼ˆå¿ƒæ‚¸ã€å‡ºæ±—ï¼‰ã€‚

ç¬¬äºŒé˜¶æ®µï¼šè½¬æ¢ä¸ç»´æŒæœŸï¼ˆç¬¬2\-4å‘¨åŠä»¥åï¼‰
----------------------------------------------------------

â— éšç€æ™®ç‘å·´æ—å‰‚é‡é€’å‡å’Œæ€¥æ€§ç—‡çŠ¶æ¶ˆé€€ï¼Œé€æ­¥å¼•å…¥å¹¶æ»´å®šæ‰˜å¡é…¯ã€‚

â— æ‰˜å¡é…¯åœ¨æ­¤é˜¶æ®µçš„ä½œç”¨æ˜¯æ¥ç®¡å¯¹è°·æ°¨é…¸ç³»ç»Ÿçš„æ§åˆ¶ï¼ŒæŠ‘åˆ¶é•¿æœŸçš„å¿ƒç†æ¸´æ±‚ï¼Œå¹¶ä½œä¸ºå¿ƒå¢ƒç¨³å®šå‰‚çš„è¾…åŠ©æˆåˆ†é¢„é˜²åŒç›¸å¤å‘ã€‚

æ‰˜å¡é…¯è¯±å‘çš„æŠ‘éƒä¸è‡ªæ€æ„å¿µ
---------------------------------------

è¿™æ˜¯æœ¬æŠ¥å‘Šå¿…é¡»å¼ºè°ƒçš„å…³é”®å®‰å…¨æ€§é—®é¢˜ã€‚å¤šä»½ç—…ä¾‹æŠ¥å‘Šå’Œè¯ç†å­¦åˆ†ææŒ‡å‡ºï¼Œæ‰˜å¡é…¯å…·æœ‰æ½œåœ¨çš„è‡´  
æŠ‘éƒå±æ€§ ã€‚

ä¸´åºŠè¡¨ç°ä¸æœºåˆ¶ï¼š

â— ç—‡çŠ¶ï¼š éƒ¨åˆ†æ‚£è€…åœ¨æœç”¨æ‰˜å¡é…¯åï¼ˆå°¤å…¶æ˜¯åœ¨å¿«é€ŸåŠ é‡æœŸï¼Œä¼šå‡ºç°ä¸¥é‡çš„å¿«æ„Ÿç¼ºå¤±ï¼‰ã€ç²¾ç¥è¿åŠ¨æ€§è¿Ÿæ»ã€æ— åŠ©æ„Ÿï¼Œç”šè‡³çªå‘çš„è‡ªæ€æ„å¿µã€‚

é«˜å±äººç¾¤ï¼š æ—¢å¾€æœ‰æŠ‘éƒå‘ä½œå²ã€åŒç›¸éšœç¢æŠ‘éƒç›¸ã€æˆ–ç²¾ç¥ç—…å²çš„æ‚£è€…é£é™©æœ€é«˜ã€‚

â— å‡è¯´æœºåˆ¶ï¼š è¿™å¯èƒ½ä¸å…¶å¼ºå¤§çš„GABAå¢å¼ºä½œç”¨å¯¼è‡´çš„è¿‡åº¦ä¸­æ¢æŠ‘åˆ¶ï¼ˆSedationï¼‰æœ‰å…³ã€‚æ­¤å¤–ï¼Œä½œä¸ºæŠ—è°·æ°¨é…¸å‰‚ï¼Œè¿‡åº¦é™ä½å‰é¢å¶çš®å±‚çš„è°·æ°¨é…¸ä¼ é€’å¯èƒ½å¯¼è‡´ç±»ä¼¼â€œé˜´æ€§ç—‡çŠ¶â€çš„æƒ…æ„Ÿæ·¡æ¼ ã€‚

ä¹Ÿæœ‰è§‚ç‚¹è®¤ä¸ºï¼Œè¿™å¯èƒ½æ¶‰åŠå…¶å¯¹è¡€æ¸…ç´ æˆ–å¤šå·´èƒºç³»ç»Ÿçš„é—´æ¥è°ƒèŠ‚å¤±è¡¡ã€‚

ä¸å…¶ä»–è¯ç‰©çš„ç›¸äº’ä½œç”¨ï¼š åœ¨Ramaswamyçš„ç—…ä¾‹ä¸­ï¼Œæ‚£è€…å¯¹æ‰˜å¡é…¯è€å—è‰¯å¥½ï¼Œè¿™å¯èƒ½ä¸åŸºå› å‹æœ‰  
å…³ã€‚ä½†åœ¨å…¶ä»–ç—…ä¾‹ä¸­ï¼Œå½“æ‰˜å¡é…¯ä¸SSRIsæˆ–å…¶ä»–å¿ƒå¢ƒç¨³å®šå‰‚åˆç”¨æ—¶ï¼Œå¯èƒ½ä¼šå‡ºç°ä¸å¯é¢„æµ‹çš„æƒ…ç»ªæ³¢  
åŠ¨ã€‚ä¾‹å¦‚ï¼Œæœ‰æŠ¥é“ç§°æ‰˜å¡é…¯å¯èƒ½è¯±å‘åŒç›¸æ‚£è€…çš„èºç‹‚å‘ä½œï¼Œå°½ç®¡è¿™è¾ƒä¸ºç½•è§ï¼Œé€šå¸¸å‘ç”Ÿåœ¨æ’¤è¯æˆ–  
å‰‚é‡æ”¹å˜æ—¶ ã€‚

é£é™©ç®¡ç†ä¸ç›‘æµ‹æŒ‡æ ‡
---------------------------

æƒ…ç»ªä¸è‡ªæ€ç›‘æµ‹ï¼š é‰´äºæ‰˜å¡é…¯çš„è‡´æŠ‘éƒé£é™©ï¼Œæ²»ç–—å‰å¿…é¡»è¿›è¡ŒåŸºçº¿æŠ‘éƒè¯„ä¼°ï¼ˆå¦‚HAM\-Dé‡è¡¨ï¼‰ã€‚åœ¨æ»´å®šæœŸé—´ï¼Œæ¯å‘¨æˆ–æ¯ä¸¤å‘¨è¿›è¡Œä¸€æ¬¡éšè®¿ï¼Œè¯¢é—®æ˜¯å¦æœ‰è‡ªæ€æ„å¿µæˆ–æ— åŠ©æ„Ÿå¢åŠ  ã€‚å¦‚æœå‡ºç°æ˜æ˜¾çš„æŠ‘éƒåŠ é‡ï¼Œåº”ç«‹å³å‡é‡æˆ–åœè¯ã€‚

è®¤çŸ¥åŠŸèƒ½ä¿æŠ¤ï¼š æ‰˜å¡é…¯è¢«ç§°ä¸ºâ€œDopamaxâ€ï¼ˆç¬¨è›‹è¯ï¼‰ï¼Œå› å…¶å¸¸å¼•èµ·è¯­è¨€æµç•…æ€§ä¸‹é™å’Œè®°å¿†åŠ›å‡é€€ã€‚åº”å»ºè®®æ‚£è€…è¡¥å……Bæ—ç»´ç”Ÿç´ ï¼Œå¹¶é¿å…ä»äº‹é«˜é£é™©æ“ä½œã€‚è‹¥è®¤çŸ¥å‰¯ä½œç”¨ä¸¥é‡å½±å“ç”Ÿæ´»ï¼Œåº”å‡æ…¢æ»´å®šé€Ÿåº¦ã€‚

ä»£è°¢æ€§é…¸ä¸­æ¯’ä¸è‚¾ç»“çŸ³ï¼š å®šæœŸç›‘æµ‹è¡€æ¸…ç¢³é…¸æ°¢ç›æ°´å¹³ã€‚å»ºè®®æ‚£è€…æ¯æ—¥é¥®æ°´è‡³å°‘2000\-3000mlï¼Œä»¥é¢„é˜²ç£·é…¸é’™ç»“çŸ³çš„å½¢æˆã€‚å¯¹äºæœ‰è‚¾ç»“çŸ³ç—…å²çš„æ‚£è€…ï¼Œåº”æƒè¡¡åˆ©å¼Šæˆ–é€‰æ‹©æ›¿ä»£è¯ç‰© ã€‚

é¿å­•å»ºè®®ï¼š æ‰˜å¡é…¯ï¼ˆå‰‚é‡\>200 mg/å¤©ï¼‰å¯è¯±å¯¼CYP3A4é…¶ï¼Œé™ä½å£æœé¿å­•è¯çš„è¡€è¯æµ“åº¦ï¼Œå¯¼è‡´é¿å­•å¤±è´¥ã€‚æ­¤å¤–ï¼Œå…¶å…·æœ‰è‡´ç•¸æ€§ï¼ˆå”‡è…­è£‚é£é™©ï¼‰ã€‚å¯¹äºè‚²é¾„æœŸå¥³æ€§æ‚£è€…ï¼Œå¿…é¡»å¼ºåˆ¶å»ºè®®ä½¿ç”¨éæ¿€ç´ ç±»é¿å­•æªæ–½ï¼ˆå¦‚å®«å†…èŠ‚è‚²å™¨æˆ–å±éšœé¿å­•ï¼‰ ã€‚

å¼•ç”¨çš„æ–‡çŒ®

1. Brief Report: A Randomized, Placebo\-Controlled Proof\-of\-Concept Trial of Adjunctive  
Topiramate for Alcohol Use Disorders in Bipolar Disorder \- NIH,  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC4791182/>

2. Lyrica Withdrawal Symptoms, Side Effects\& Detox Treatment \- American Addiction Centers,  
<https://americanaddictioncenters.org/prescription-drugs/lyrica-withdrawal-symptoms>

3. A case report of pregabalin misuse leading to drug dependence \- Frontiers,  
<https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1511168/full>

4. Psychopharmacology of topiramate: from epilepsy to bipolar disorder \- PubMed Central,  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC2671954/>

5. Topiramate Pharmacotherapy for Alcohol Use Disorder and Other Addictions: A Narrative Review \- Center for Care Innovations,  
<https://www.careinnovations.org/wp-content/uploads/Topiramate_Pharmacotherapy_for_Alcohol_Use.99441.pdf>

6. Robotripping: The Dangers of Abusing Dextromethorphan \- Rowan Digital  
Works, <https://rdw.rowan.edu/cgi/viewcontent.cgi?article=1154&context=stratford_research_day>

7. (PDF) Pregabalin Dependence: A Case Report \- ResearchGate,  
<https://www.researchgate.net/publication/276044014_Pregabalin_Dependence_A_Case_Report>

8. Acute Pregabalin Withdrawal: A Case Report and Review of the Literature \- Southwest  
Journal of Pulmonary, Critical Care and Sleep, <https://www.swjpcc.com/critical-care/2015/5/29/acute-pregabalin-withdrawal-a-case-report-and-review-of-the.html>

9. Selective Antagonism of GluR5 Kainate\-Receptor\-Mediated Synaptic Currents by Topiramate in Rat Basolateral Amygdala Neurons \| Journal of Neuroscience, <https://www.jneurosci.org/content/23/18/7069>

10. Topiramate has no effect on AMPA receptor\-mediated enhancement of the... \- ResearchGate,  
<https://www.researchgate.net/figure/Topiramate-has-no-effect-on-AMPA-receptor-mediated-enh>  
ancement\-of\-the\-spontaneous\_fig3\_24403386

11. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist \- PubMed, <https://pubmed.ncbi.nlm.nih.gov/15111016/>

12. TOPIRAMATE IN THE NEW GENERATION OF DRUGS: EFFICACY IN THE TREATMENT OF ALCOHOLIC PATIENTS \- PMC \- PubMed  
Central, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3063512/>

13. What is the mechanism of Topiramate? \- Patsnap Synapse,  
<https://synapse.patsnap.com/article/what-is-the-mechanism-of-topiramate>

14. Mechanisms of action of antiepileptic drugs \- Epilepsy Society,  
<https://epilepsysociety.org.uk/sites/default/files/2020-08/Chapter25Sills2015.pdf>

15. Topiramate \- StatPearls \- NCBI Bookshelf \- NIH, <https://www.ncbi.nlm.nih.gov/books/NBK554530/>

16. Topiramate via NMDA, AMPA/kainate, GABAA and Alpha2 receptors and by modulation of  
CREB/BDNF and Akt/GSK3 signaling pathway exerts neuroprotective effects against  
methylphenidate\-induced neurotoxicity in rats \- PubMed,  
<https://pubmed.ncbi.nlm.nih.gov/28795276/>

17. Dextromethorphan Addiction Mediated Through the NMDA System: Common Pathways With Alcohol? \- PubMed,  
<https://pubmed.ncbi.nlm.nih.gov/26441400/>

18. Topiramate in dextromethorphan abuse \- PubMed, <https://pubmed.ncbi.nlm.nih.gov/26554372/>

19. Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice \- PubMed, <https://pubmed.ncbi.nlm.nih.gov/22017514/>

20. Alcohol Withdrawal Syndrome: Outpatient Management \- AAFP,<https://www.aafp.org/pubs/afp/issues/2021/0900/p253.html>

21. Can Topiramate Treat Alcohol  
Addiction?, <https://americanaddictioncenters.org/addiction-medications/topiramate>

22. Gabapentin: A new addition to the armamentarium for alcohol dependence? \- PMC \- NIH,  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC4054701/>

23. Topiramate for acute affective episodes in bipolar disorder in adults \- Pigott, K \- 2016,  
<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003384.pub3/full>

24. Review of the use of Topiramate for treatment of psychiatric disorders \- PubMed Central,  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC1088011/>

25. Preliminary findings on topiramate foraddressing health behaviors in comorbid bipolar disorder and alcohol use disorder \- NIH, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7666643/>

26. Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse \- PubMed, <https://pubmed.ncbi.nlm.nih.gov/16009565/>

27. Topiramate in Bipolar Disorder and Comorbidities: The Myths and the Evidence,  
<https://www.psychiatrictimes.com/view/topiramate-bipolar-disorder-comorbidities-the-myths-evid>  
ence

28. Topiramate precipitating mania in bipolar disorder \- PMC \- NIH, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4888705/>

29. Topiramate\-Induced Depression \| American Journal of Psychiatry, <https://psychiatryonline.org/doi/10.1176/appi.ajp.158.10.1736>

30. Topiramate precipitating a manic episode in a bipolar patient comorbid with binge eating disorder: A case report \- PMC \- PubMed Central, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6831447/>

31. Topiramate\-induced Dissociative Disorder \- PubMed, <https://pubmed.ncbi.nlm.nih.gov/21922065/>

32. Topiramate\-induced Dissociative Disorder \- PMC \- NIH, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3173756/>

33. Topamax \- accessdata.fda.gov,<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020505s067,020844s058lbl.pdf>

34. Topiramate Dosage Guide \+ Max Dose, Adjustments \- Drugs.com,  
<https://www.drugs.com/dosage/topiramate.html>

35. Study Details \| NCT00167245 \| Topiramate for Alcohol and Cocaine Dependence \| ClinicalTrials.gov,  
<https://clinicaltrials.gov/study/NCT00167245>

36. AUD\-Patient AD\-Topiramate,  
<https://www.pbm.va.gov/PBM/AcademicDetailingService/Documents/Academic_Detailing_Educational_Material_Catalog/15_AUD_Patient_AD_Topiramate_Factsheet.pdf>

37. A double\-blind, placebo\-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol  
dependence \- NIH, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3786029/>

38. The Initiation, Management and Discontinuation of Pregabalin and Gabapentin prescribing for neuropathic  
pain in Primary Care, <https://www.hey.nhs.uk/wp/wp-content/uploads/2016/03/pregabalin.pdf>

39. Gabapentin Withdrawal Symptoms, Signs \& Side Effects \- American Addiction Centers,  
<https://americanaddictioncenters.org/neurontin-abuse/gabapentin-cause-withdrawal-symptoms>

40. Considerations for Crisis Centers and Clinicians in Managing the Treatment of Alcohol or Benzodiazepine Withdrawal during the CO \- SAMHSA,  
<https://www.samhsa.gov/sites/default/files/considerations-crisis-centers-clinicians-treatment-alcohol-benzodiazepine-withdrawal.pdf>

41. Topiramate (oral route) \- Side effects \& dosage \- Mayo Clinic,  
<https://www.mayoclinic.org/drugs-supplements/topiramate-oral-route/description/drg-20067047>

42. Lyrica and topiramate Interactions Checker \- Drugs.com,  
<https://www.drugs.com/drug-interactions/lyrica-with-topiramate-1937-2171-2216-0.html>

[ä¸Šä¸€ç¯‡ é…¸ç¢±DXMèƒå–æ³•](896.md "é…¸ç¢±DXMèƒå–æ³•")[ä¸‹ä¸€ç¯‡ å…³äºæ™®ç‘å·´æ—çš„ä¸€äº›ä¸ªäººå¿ å‘Š](573.md "å…³äºæ™®ç‘å·´æ—çš„ä¸€äº›ä¸ªäººå¿ å‘Š")
